Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer.

Dagogo-Jack I, Azzolli CG, Fintelmann F, Mino-Kenudson M, Farago AF, Gainor JF, Jiang G, Piotrowska Z, Heist RS, Lennes IT, Temel JS, Mooradian MJ, Lin JJ, Digumarthy SR, Batten JM, Robinson H, Nose V, Rivera M, Nardi V, Dias-Santagata D, Le LP, Sequist LV, Pitman M, Shepard JO, Shaw AT, Iafrate AJ, Lennerz JK.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00299. Epub 2018 Jul 24.

2.

Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions.

Piotrowska Z, Costa DB, Oxnard GR, Huberman M, Gainor JF, Lennes IT, Muzikansky A, Shaw AT, Azzoli CG, Heist RS, Sequist LV.

Ann Oncol. 2018 Oct 1;29(10):2092-2097. doi: 10.1093/annonc/mdy336.

PMID:
30351341
3.

A Patient-Centered Utility Index for Non-Small Cell Lung Cancer in the United States.

Swan JS, Lennes IT, Stump NN, Temel JS, Wang D, Keller L, Donelan K.

MDM Policy Pract. 2018 Oct 15;3(2):2381468318801565. doi: 10.1177/2381468318801565. eCollection 2018 Jul-Dec.

4.

Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.

Piotrowska Z, Isozaki H, Lennerz JK, Gainor JF, Lennes IT, Zhu VW, Marcoux N, Banwait MK, Digumarthy SR, Su W, Yoda S, Riley AK, Nangia V, Lin JJ, Nagy RJ, Lanman RB, Dias-Santagata D, Mino-Kenudson M, Iafrate AJ, Heist RS, Shaw AT, Evans EK, Clifford C, Ou SI, Wolf B, Hata AN, Sequist LV.

Cancer Discov. 2018 Dec;8(12):1529-1539. doi: 10.1158/2159-8290.CD-18-1022. Epub 2018 Sep 26.

PMID:
30257958
5.

Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer.

Lin JJ, Chin E, Yeap BY, Ferris LA, Kamesan V, Lennes IT, Sequist LV, Heist RS, Mino-Kenudson M, Gainor JF, Shaw AT.

J Thorac Oncol. 2018 Sep 8. pii: S1556-0864(18)33040-5. doi: 10.1016/j.jtho.2018.09.001. [Epub ahead of print]

PMID:
30205166
6.

Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer.

Piotrowska Z, Hazar-Rethinam M, Rizzo C, Nadres B, Van Seventer EE, Shahzade HA, Lennes IT, Iafrate AJ, Dias-Santagata D, Leshchiner I, Jessop NA, Hu H, Digumarthy SR, Nagy RJ, Lanman RB, Moody S, Niederst MJ, Engelman JA, Hata AN, Corcoran RB, Sequist LV.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00263. Epub 2018 Jul 16.

7.

Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.

Wood DE, Kazerooni EA, Baum SL, Eapen GA, Ettinger DS, Hou L, Jackman DM, Klippenstein D, Kumar R, Lackner RP, Leard LE, Lennes IT, Leung ANC, Makani SS, Massion PP, Mazzone P, Merritt RE, Meyers BF, Midthun DE, Pipavath S, Pratt C, Reddy C, Reid ME, Rotter AJ, Sachs PB, Schabath MB, Schiebler ML, Tong BC, Travis WD, Wei B, Yang SC, Gregory KM, Hughes M.

J Natl Compr Canc Netw. 2018 Apr;16(4):412-441. doi: 10.6004/jnccn.2018.0020.

PMID:
29632061
8.

Project reach: Piloting a risk-tailored smoking cessation intervention for lung screening.

Lennes IT, Luberto CM, Carr AL, Hall DL, Strauss NM, Ponzani C, Park ER.

J Health Psychol. 2018 Feb 1:1359105318756500. doi: 10.1177/1359105318756500. [Epub ahead of print]

PMID:
29502458
9.

Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA.

Dagogo-Jack I, Brannon AR, Ferris LA, Campbell CD, Lin JJ, Schultz KR, Ackil J, Stevens S, Dardaei L, Yoda S, Hubbeling H, Digumarthy SR, Riester M, Hata AN, Sequist LV, Lennes IT, Iafrate AJ, Heist RS, Azzoli CG, Farago AF, Engelman JA, Lennerz JK, Benes CH, Leary RJ, Shaw AT, Gainor JF.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00160. Epub 2018 Jan 23.

10.

Lung Cancer Screening Uncertainty among Patients Undergoing LDCT.

Hall DL, Lennes IT, Carr A, Eusebio JR, Yeh GY, Park ER.

Am J Health Behav. 2018 Jan 1;42(1):69-76. doi: 10.5993/AJHB.42.1.7.

PMID:
29320340
11.

Are cancer survivors following the national comprehensive cancer network health behavior guidelines? An assessment of patients attending a cancer survivorship clinic.

Hyland KA, Jacobs JM, Lennes IT, Pirl WF, Park ER.

J Psychosoc Oncol. 2018 Jan-Feb;36(1):64-81. doi: 10.1080/07347332.2017.1399193.

PMID:
29303476
12.

The relationship between physical and psychological symptoms and health care utilization in hospitalized patients with advanced cancer.

Nipp RD, El-Jawahri A, Moran SM, D'Arpino SM, Johnson PC, Lage DE, Wong RL, Pirl WF, Traeger L, Lennes IT, Cashavelly BJ, Jackson VA, Greer JA, Ryan DP, Hochberg EP, Temel JS.

Cancer. 2017 Dec 1;123(23):4720-4727. doi: 10.1002/cncr.30912. Epub 2017 Oct 23.

13.

Lung Cancer Screening: Why, When, and How?

Fintelmann FJ, Gottumukkala RV, McDermott S, Gilman MD, Lennes IT, Shepard JO.

Radiol Clin North Am. 2017 Nov;55(6):1163-1181. doi: 10.1016/j.rcl.2017.06.003. Review.

PMID:
28991558
14.

Managing Patients With Screen-Detected Nodules: The Nodule Clinic.

Campo MJ, Lennes IT.

Semin Roentgenol. 2017 Jul;52(3):161-165. doi: 10.1053/j.ro.2017.06.005. Epub 2017 Jun 3. Review. No abstract available.

PMID:
28734398
15.

Treatment Satisfaction and Adherence to Oral Chemotherapy in Patients With Cancer.

Jacobs JM, Pensak NA, Sporn NJ, MacDonald JJ, Lennes IT, Safren SA, Pirl WF, Temel JS, Greer JA.

J Oncol Pract. 2017 May;13(5):e474-e485. doi: 10.1200/JOP.2016.019729. Epub 2017 Apr 11.

PMID:
28398843
16.

MINI01.17: Project Reach: Piloting a Risk-Tailored Smoking Cessation Intervention for Lung Screening: Topic: Pulmonology.

Lennes IT, Strauss N, Luberto C, Eusebio J, Park ER.

J Thorac Oncol. 2016 Nov;11(11S):S267. doi: 10.1016/j.jtho.2016.09.032. Epub 2016 Oct 28. No abstract available.

17.

Fear of recurrence or progression as a link between somatic symptoms and perceived stress among cancer survivors.

Hall DL, Lennes IT, Pirl WF, Friedman ER, Park ER.

Support Care Cancer. 2017 May;25(5):1401-1407. doi: 10.1007/s00520-016-3533-3. Epub 2016 Dec 13.

18.

Pilot Study of a Patient-Centered Radiology Process Model.

Swan JS, Furtado VF, Keller LA, Lotti JB, Saltalamacchia CA, Lennes IT, Salazar GM.

J Am Coll Radiol. 2017 Feb;14(2):274-281. doi: 10.1016/j.jacr.2016.08.024. Epub 2016 Dec 4.

PMID:
27927589
19.

Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping.

Dagogo-Jack I, Gainor JF, Porter RL, Schultz KR, Solomon BJ, Stevens S, Azzoli CG, Sequist LV, Lennes IT, Shaw AT.

J Thorac Oncol. 2016 Sep;11(9):1522-8. doi: 10.1016/j.jtho.2016.05.031. Epub 2016 Jun 11.

20.

Quality of psychosocial services in cancer centers: Today and tomorrow.

Pirl WF, Lennes IT.

Cancer. 2016 Jun 15;122(12):1807-8. doi: 10.1002/cncr.30018. Epub 2016 Apr 12. No abstract available.

21.

Chemotherapy Errors: A Call for a Standardized Approach to Measurement and Reporting.

Lennes IT, Bohlen N, Park ER, Mort E, Burke D, Ryan DP.

J Oncol Pract. 2016 Apr;12(4):e495-501. doi: 10.1200/JOP.2015.008995. Epub 2016 Mar 8.

PMID:
26957639
22.

Timeliness of Recommended Follow-Up After an Abnormal Finding on Diagnostic Chest CT in Smokers at High Risk of Developing Lung Cancer.

Percac-Lima S, Ashburner JM, Shepard JA, Lennes IT, Rimmelin DE, Atlas SJ.

J Am Coll Radiol. 2016 May;13(5):497-504. doi: 10.1016/j.jacr.2016.01.007. Epub 2016 Feb 28.

PMID:
26924163
23.

The 10 Pillars of Lung Cancer Screening: Rationale and Logistics of a Lung Cancer Screening Program.

Fintelmann FJ, Bernheim A, Digumarthy SR, Lennes IT, Kalra MK, Gilman MD, Sharma A, Flores EJ, Muse VV, Shepard JA.

Radiographics. 2015 Nov-Dec;35(7):1893-908. doi: 10.1148/rg.2015150079. Epub 2015 Oct 23. Review.

PMID:
26495797
24.

Psychological factors at early stage of treatment as predictors of receiving chemotherapy at the end of life.

Fujisawa D, Temel JS, Traeger L, Greer JA, Lennes IT, Mimura M, Pirl WF.

Psychooncology. 2015 Dec;24(12):1731-7. doi: 10.1002/pon.3840. Epub 2015 May 8.

PMID:
25959002
25.

Processes of discontinuing chemotherapy for metastatic non-small-cell lung cancer at the end of life.

Pirl WF, Greer JA, Irwin K, Lennes IT, Jackson VA, Park ER, Fujisawa D, Wright AA, Temel JS.

J Oncol Pract. 2015 May;11(3):e405-12. doi: 10.1200/JOP.2014.002428. Epub 2015 Mar 31.

26.

Sexual health communication between cancer survivors and providers: how frequently does it occur and which providers are preferred?

Sporn NJ, Smith KB, Pirl WF, Lennes IT, Hyland KA, Park ER.

Psychooncology. 2015 Sep;24(9):1167-73. doi: 10.1002/pon.3736. Epub 2014 Dec 22.

PMID:
25534170
27.

Genotyping lung cancer is an investment in the future.

Azzoli CG, Engelman J, Fidias P, Gainor JF, Heist RS, Lamont EB, Lennes IT, Rosovsky RP, Sequist LV, Shaw AT, Temel JS.

J Clin Oncol. 2014 Nov 1;32(31):3576-7. doi: 10.1200/JCO.2014.56.6430. Epub 2014 Sep 8. No abstract available.

PMID:
25199750
28.

Perceptions of health status and survival in patients with metastatic lung cancer.

Greer JA, Pirl WF, Jackson VA, Muzikansky A, Lennes IT, Gallagher ER, Prigerson HG, Temel JS.

J Pain Symptom Manage. 2014 Oct;48(4):548-57. doi: 10.1016/j.jpainsymman.2013.10.016. Epub 2014 Mar 27.

PMID:
24680623
29.

Massachusetts general hospital: improving patient access to the breast oncology clinic.

Lennes IT, Bloom M, Bohlen N, Moy B.

J Natl Compr Canc Netw. 2014 Feb;12 Suppl 1:S25-7.

PMID:
24614048
30.

Documentation of oral versus intravenous chemotherapy plans in patients with metastatic non-small-cell lung cancer.

Greer JA, Lennes IT, Gallagher ER, Temel JS, Pirl WF.

J Oncol Pract. 2014 Mar;10(2):e103-6. doi: 10.1200/JOP.2013.001154. Epub 2014 Jan 28.

31.

Associations among prognostic understanding, quality of life, and mood in patients with advanced cancer.

El-Jawahri A, Traeger L, Park ER, Greer JA, Pirl WF, Lennes IT, Jackson VA, Gallagher ER, Temel JS.

Cancer. 2014 Jan 15;120(2):278-85. doi: 10.1002/cncr.28369. Epub 2013 Oct 10.

32.

Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors.

Goldberg SB, Oxnard GR, Digumarthy S, Muzikansky A, Jackman DM, Lennes IT, Sequist LV.

Oncologist. 2013;18(11):1214-20. doi: 10.1634/theoncologist.2013-0168. Epub 2013 Sep 26.

33.

Non-small cell lung cancer, version 2.2013.

Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW Jr, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M; National comprehensive cancer network.

J Natl Compr Canc Netw. 2013 Jun 1;11(6):645-53; quiz 653.

PMID:
23744864
34.

Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology.

Ettinger DS, Riely GJ, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW Jr, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2013 May 1;11(5):562-76.

PMID:
23667206
35.

Depression, survival, and epidermal growth factor receptor genotypes in patients with metastatic non-small cell lung cancer.

Pirl WF, Traeger L, Greer JA, Jackson V, Lennes IT, Gallagher E, Sequist L, Temel JS.

Palliat Support Care. 2013 Jun;11(3):223-9. doi: 10.1017/S1478951512001071. Epub 2013 Feb 11.

PMID:
23399428
36.

Electronic prompt to improve outpatient code status documentation for patients with advanced lung cancer.

Temel JS, Greer JA, Gallagher ER, Jackson VA, Lennes IT, Muzikansky A, Park ER, Pirl WF.

J Clin Oncol. 2013 Feb 20;31(6):710-5. doi: 10.1200/JCO.2012.43.2203. Epub 2013 Jan 2.

PMID:
23284038
37.

Non-small cell lung cancer.

Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW Jr, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, Hughes M, Gregory KM; NCCN (National Comprehensive Cancer Network).

J Natl Compr Canc Netw. 2012 Oct 1;10(10):1236-71.

PMID:
23054877
38.

Predictors of newly diagnosed cancer patients' understanding of the goals of their care at initiation of chemotherapy.

Lennes IT, Temel JS, Hoedt C, Meilleur A, Lamont EB.

Cancer. 2013 Feb 1;119(3):691-9. doi: 10.1002/cncr.27787. Epub 2012 Sep 25.

39.

The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement.

Martins RG, D'Amico TA, Loo BW Jr, Pinder-Schenck M, Borghaei H, Chaft JE, Ganti AK, Kong FM, Kris MG, Lennes IT, Wood DE.

J Natl Compr Canc Netw. 2012 May;10(5):599-613. Review.

PMID:
22570291
40.

Depression and survival in metastatic non-small-cell lung cancer: effects of early palliative care.

Pirl WF, Greer JA, Traeger L, Jackson V, Lennes IT, Gallagher ER, Perez-Cruz P, Heist RS, Temel JS.

J Clin Oncol. 2012 Apr 20;30(12):1310-5. doi: 10.1200/JCO.2011.38.3166. Epub 2012 Mar 19.

41.

Malignant pleural mesothelioma.

Ettinger DS, Akerley W, Borghaei H, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Schenck MP, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Jan;10(1):26-41. No abstract available.

PMID:
22223867
42.

Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer.

Greer JA, Pirl WF, Jackson VA, Muzikansky A, Lennes IT, Heist RS, Gallagher ER, Temel JS.

J Clin Oncol. 2012 Feb 1;30(4):394-400. doi: 10.1200/JCO.2011.35.7996. Epub 2011 Dec 27.

PMID:
22203758
43.

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice.

Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, Lennes IT, Digumarthy S, Waltman BA, Bast E, Tammireddy S, Morrissey L, Muzikansky A, Goldberg SB, Gainor J, Channick CL, Wain JC, Gaissert H, Donahue DM, Muniappan A, Wright C, Willers H, Mathisen DJ, Choi NC, Baselga J, Lynch TJ, Ellisen LW, Mino-Kenudson M, Lanuti M, Borger DR, Iafrate AJ, Engelman JA, Dias-Santagata D.

Ann Oncol. 2011 Dec;22(12):2616-24. doi: 10.1093/annonc/mdr489. Epub 2011 Nov 9.

44.

Anxiety disorders in long-term survivors of adult cancers.

Greer JA, Solis JM, Temel JS, Lennes IT, Prigerson HG, Maciejewski PK, Pirl WF.

Psychosomatics. 2011 Sep-Oct;52(5):417-23. doi: 10.1016/j.psym.2011.01.014.

45.

Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care.

Temel JS, Greer JA, Admane S, Gallagher ER, Jackson VA, Lynch TJ, Lennes IT, Dahlin CM, Pirl WF.

J Clin Oncol. 2011 Jun 10;29(17):2319-26. doi: 10.1200/JCO.2010.32.4459. Epub 2011 May 9.

PMID:
21555700
46.

Thymic malignancies.

Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW Jr, Jahan T, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2010 Nov;8(11):1302-15. No abstract available.

PMID:
21081786
47.

Non-small cell lung cancer.

Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Jahan T, Jahanzeb M, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Simon GR, Swanson SJ, Wood DE, Yang SC; NCCN Non-Small Cell Lung Cancer Panel Members.

J Natl Compr Canc Netw. 2010 Jul;8(7):740-801. Review. No abstract available.

PMID:
20679538
48.

Quality indicators in cancer care: development and implementation for improved health outcomes in non-small-cell lung cancer.

Lennes IT, Lynch TJ.

Clin Lung Cancer. 2009 Sep;10(5):341-6. doi: 10.3816/CLC.2009.n.046. Review.

PMID:
19808192

Supplemental Content

Loading ...
Support Center